Merck to acquire immuno-oncology firm for $137m

08-09-2017

Merck to acquire immuno-oncology firm for $137m

ricul-1 / iStockphoto.com

Merck has revealed plans to boost its immune-oncology expertise with the acquisition of Germany-based Rigontec.


Merck, Rigontec, biopharmaceutical, University of Bonn, Eric Rubin, Christian Schetter, mergers & acquisitions,

More on this story

Alnylam acquires Merck’s RNAi assets and IP
13-01-2014

LSIPR